GW5282 + golidocitinib

GW5282 + golidocitinib is an investigational combination therapy, referred to as the G2 regimen, being developed by Dizal Pharmaceuticals for the treatment of T-cell lymphomas. Golidocitinib (DZD4205) is a potent and highly selective oral Janus kinase 1 (JAK1) inhibitor that has already received approval in China for relapsed or refractory peripheral T-cell lymphoma (PTCL). GW5282 is a small molecule inhibitor of SHP2 (Src homology 2 domain-containing protein tyrosine phosphatase 2), a protein that plays a critical role in various signaling pathways, including the RAS/MAPK pathway, which is often dysregulated in hematologic malignancies. The combination is designed to provide synergistic anti-tumor activity by simultaneously blocking the JAK/STAT and SHP2-mediated signaling pathways, potentially overcoming resistance mechanisms associated with monotherapy. It is currently being evaluated in Phase 1/2 clinical trials to compare its efficacy and safety against standard chemotherapy regimens like CHOP.

Other names

GW5282 and golidocitinibGW-5282 and golidocitinibGW 5282 and golidocitinib